Vesugen
Vesugen is a synthetic tripeptide (Lys-Glu-Asp, abbreviated KED) from the Khavinson bioregulator program, derived from aortic tissue and studied as a vascular-endothelium signalling molecule; research protocols typically use 10 mg sublingually each morning in short 10-20 day courses. It is among the better-represented peptides in this class on PubMed, though the human data remains small, Russian-language, and unreplicated.
Adults researching the Khavinson bioregulator class for vascular-aging signalling. It is a research-interest compound, not a treatment for atherosclerosis, hypertension, or peripheral vascular disease, and it does not substitute for cardiovascular care.
Vesugen is the tripeptide Lys-Glu-Asp, isolated conceptually from aortic tissue extracts and synthesized as a defined molecule by Khavinson's group in St. Petersburg. Its proposed mechanism is transcriptional.
A 2014 Russian-language paper reported that Vesugen increased expression of Ki-67, a proliferation-associated protein that declines with age, in tissue-specific cultures from young and old animals and in dissociated vascular endothelial cell cultures; molecular docking in the same work placed the peptide in contact with the core promoter region of the MKI67 gene near the transcriptional start site, which the authors offered as an epigenetic explanation for the vasoprotective effect they attribute to it. A 2012 study reported that Vesugen, alongside the tissue-matched peptides pancragen and bronchogen, selectively restored tissue-appropriate differentiation markers in late-passage (aging) cell cultures — the effect being more pronounced in the aged cultures, which is the group's proposed geroprotective signature. More recent work has extended KED into neurogenesis and Alzheimer's-model contexts.
A 2022 review from the same group lists the KED tripeptide among vasoprotective peptides said to regulate inflammaging and senescence-associated secretory phenotype molecules in cardiovascular cells. The honest summary: the mechanistic story is coherent and internally consistent, but it originates almost entirely from one research group, most of it is in vitro or animal work, and the human data amounts to small Russian-language cohorts that no independent group has replicated. There is no Western regulatory approval and no controlled trial establishing a clinical vascular outcome.
Sublingual, once daily in the morning. The catalog reference is 10 mg per day, with a research range of 5-20 mg (5 mg as a conservative start, 20 mg at the high end), taken as cyclic 10-20 day courses rather than continuously. Research references only.
- Peak
- Not established — no human pharmacokinetic study published
- Bioavailability
- Not measured in humans
No validated human onset window. The cyclic 10-20 day course reflects dosing convention in the source literature rather than any measured time-to-effect.
Grouped in the bioregulator literature with the other tissue-directed Khavinson peptides — Cardiogen (cardiac), Livagen (liver), Testagen (reproductive tissue) — conventionally as separate short courses rather than a simultaneous stack. No combination has been studied.
- Peptides tissue-specifically stimulate cell differentiation during their aging
- Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
- PubChem - Lysyl-glutamyl-aspartic acid (KED) Compound Summary, CID 87571363
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.